Testing HM15275 in Adults With Type 2 Diabetes
Tests HM15275 against a placebo in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Key facts
- Where
- Chicago, Columbus, DeLand, Fremont, Jefferson City, Kansas City, Las Vegas, Manassas, Mesa, Morehead City, Orlando, Salt Lake City, Santa Clarita, South Bend, The Villages, and Tomball, United StatesSee the 20 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07527650, who can take part
Where in United States
- Charter Research ChicagoChicago, United StatesTaking people
- Centricity Research ColumbusColumbus, United StatesTaking people
- Centricity Research IRT - DBA IACT Health Columbus PiedmontColumbus, United StatesTaking people
- Accel Research Sites DeLandDeLand, United StatesTaking people
- Methodist Physicians ClinicFremont, United StatesTaking people
- Jefferson City Medical CenterJefferson City, United StatesTaking people
- Clay Platte Family MedicineKansas City, United StatesTaking people
- Santa Rosa Medical Centers of NevadaLas Vegas, United StatesTaking people
- Manassas Clinical Research CenterManassas, United StatesTaking people
- Desert Clinical ResearchMesa, United StatesTaking people
- Lucas Research, Inc.Morehead City, United StatesTaking people
- AdventHealth Translational Research InstituteOrlando, United StatesTaking people
- Charter ResearchOrlando, United StatesTaking people
- Highland Clinical ResearchSalt Lake City, United StatesTaking people
- Olympus Family MedicineSalt Lake City, United StatesTaking people
- Care Access Research - Santa ClaritaSanta Clarita, United StatesTaking people
- The South Bend ClinicSouth Bend, United StatesTaking people
- Charter Research The VillagesThe Villages, United StatesTaking people
- K2 Medical Research The Villages LLCThe Villages, United StatesTaking people
- DM Clinical ResearchTomball, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hanmi Pharmaceutical Company Limited
- Trial code
- NCT07527650
- Record updated
- 19 October 2026
- Original description
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.Read full original descriptionShow less
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Inclusion: Participant's age at the time of signing the informed consent:; United States: 18 to 75 years (inclusive); Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening; Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for at least 3 months prior to screening; BMI ≥25 kg/m² and ≤50 kg/m²; Body weight change <5% over the past 3 months prior to screening; Capable of giving signed informed consent and willing to comply with all protocol procedures.
Exclusion: Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening; History of diabetic ketoacidosis or severe hypoglycemia within 6 months; Clinically significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months); History of pancreatitis or factors increasing the risk of pancreatitis; Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2; Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening; Poor glycemic control (fasting plasma glucose >270 mg/dL); Clinically significant liver disease, renal impairment (eGFR <60 mL/min/1.73 m²), or abnormal laboratory findings at screening.